DGX

DGX

USD

Quest Diagnostics Incorporated Common Stock

$178.030-1.320 (-0.736%)

即時價格

Healthcare
Diagnostics & Research
美國

價格圖表

Loading Chart...

關鍵指標

市場指標
公司基本面
交易統計

市場指標

開盤

$179.350

最高

$180.040

最低

$176.310

交易量

0.20M

公司基本面

市值

19.8B

行業

Diagnostics & Research

國家

United States

交易統計

平均交易量

0.90M

交易所

NYQ

貨幣

USD

52週範圍

最低 $148.7當前 $178.030最高 $197.55

相關新聞

PR Newswire

New Study Demonstrates Accuracy of Two Quest AD-Detect® Tests for Alzheimer's Disease Diagnosis

Two blood tests, each involving multiple biomarkers, are highly accurate at identifying Alzheimer's disease pathology in symptomatic patients,...

查看更多
New Study Demonstrates Accuracy of Two Quest AD-Detect® Tests for Alzheimer's Disease Diagnosis
Analyst Upgrades

Barclays Maintains Equal-Weight on Quest Diagnostics, Raises Price Target to $195

Barclays analyst Stephanie Davis maintains Quest Diagnostics with a Equal-Weight and raises the price target from $190 to $195.

查看更多
Barclays Maintains Equal-Weight on Quest Diagnostics, Raises Price Target to $195
Analyst Upgrades

Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $205

Truist Securities analyst David Macdonald maintains Quest Diagnostics with a Hold and raises the price target from $195 to $205.

查看更多
Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $205
Analyst Upgrades

Leerink Partners Maintains Outperform on Quest Diagnostics, Raises Price Target to $210

Leerink Partners analyst Michael Cherny maintains Quest Diagnostics with a Outperform and raises the price target from $203 to $210.

查看更多
Leerink Partners Maintains Outperform on Quest Diagnostics, Raises Price Target to $210
PR Newswire

Quest Diagnostics Reports Third Quarter 2025 Financial Results; Raises Guidance for Full Year 2025

Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the third...

查看更多
Quest Diagnostics Reports Third Quarter 2025 Financial Results; Raises Guidance for Full Year 2025
Analyst Upgrades

Evercore ISI Group Maintains In-Line on Quest Diagnostics, Raises Price Target to $190

Evercore ISI Group analyst Elizabeth Anderson maintains Quest Diagnostics with a In-Line and raises the price target from $185 to $190.